HC Wainwright Has Negative Outlook of Kamada FY2027 Earnings

Key Points

• HC Wainwright lowered Kamada’s FY2027 EPS estimate to $0.56 from $0.64, though it remains above the current consensus estimate of $0.45. The firm projects EPS of $0.69 for FY2028 and $0.74 for FY2029.
• Kamada recently reported quarterly EPS of $0.16, beating the $0.11 analyst consensus, while revenue of $54.92 million exceeded estimates of $50.84 million.
• Analyst sentiment remains broadly positive, with an average “Buy” rating and a $13.00 consensus price target versus the stock’s recent opening price of $7.58. Institutional investors own 20.38% of the company.

Kamada Ltd. (NASDAQ:KMDA - Free Report) - Stock analysts at HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for shares of Kamada in a note issued to investors on Friday, August 14th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of $0.56 for the year, down from their prior forecast of $0.64. The consensus estimate for Kamada's current full-year earnings is $0.45 per share. HC Wainwright also issued estimates for Kamada's FY2028 earnings at $0.69 EPS and FY2029 earnings at $0.74 EPS.

Several other analysts have also weighed in on the stock. Weiss Ratings lowered shares of Kamada from a "buy (b)" rating to a "buy (b-)" rating in a research note on Thursday, June 25th. Benchmark restated a "buy" rating on shares of Kamada in a research report on Tuesday, July 21st. Wall Street Zen upgraded shares of Kamada from a "hold" rating to a "strong-buy" rating in a research report on Saturday. Finally, William Blair set a $15.00 price target on shares of Kamada in a report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $13.00.

Kamada Price Performance

Shares of KMDA opened at $7.58 on Monday. The business's fifty day moving average price is $7.22 and its 200 day moving average price is $7.96. Kamada has a 12-month low of $6.50 and a 12-month high of $9.35. The stock has a market capitalization of $435.93 million, a PE ratio of 19.95, a price-to-earnings-growth ratio of 0.67 and a beta of 0.86.

Kamada (NASDAQ:KMDA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.05. The business had revenue of $54.92 million during the quarter, compared to the consensus estimate of $50.84 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KMDA. Aristides Capital LLC grew its stake in Kamada by 4.5% during the 1st quarter. Aristides Capital LLC now owns 34,491 shares of the biotechnology company's stock worth $288,000 after buying an additional 1,476 shares during the last quarter. NewEdge Advisors LLC increased its position in Kamada by 9.2% in the fourth quarter. NewEdge Advisors LLC now owns 57,538 shares of the biotechnology company's stock worth $406,000 after buying an additional 4,870 shares during the period. XTX Topco Ltd bought a new stake in Kamada in the fourth quarter valued at $103,000. Quadrature Capital Ltd lifted its stake in Kamada by 53.5% in the fourth quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company's stock valued at $155,000 after buying an additional 7,627 shares during the last quarter. Finally, Man Group plc lifted its stake in Kamada by 19.9% in the fourth quarter. Man Group plc now owns 34,294 shares of the biotechnology company's stock valued at $242,000 after buying an additional 5,684 shares during the last quarter. Institutional investors and hedge funds own 20.38% of the company's stock.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source